Dengue vaccination program

Dengue, Now a Vaccine Preventable Disease

Dengue is an acute febrile illness caused by one of the four dengue serotypes (DENV-1, DENV-2, DENV-3 and DENV-4), and transmitted by Aedes mosquitoes. Infection with dengue virus can cause a spectrum of illness ranging from asymptomatic infections or self-limiting influenza-like illness to life-threatening manifestations with severe hemorrhage and vascular leakage, that can potentially lead to vascular shock and even death.There is no specific treatment for dengue; the standard of care is supportive treatment. Current strategies for disease control rely on early diagnosis, appropriate case management, and vector control programs.

During the past five decades, dengue incidence has increased 30-fold, making it one of the fastest-spreading vector-borne diseases. The disease is now endemic in 128 countries, and it is estimated that,worldwide, 3.9 billion people are currently at risk of infection. Nowadays, severe forms of dengue affect most Asian and Latin American countries where it has become a leading cause of hospitalization and death, particularly among the pre-adolescent and young adult populations.

As of December 2015, dengue is a vaccine preventable disease. The CYD-TDV vaccine (commercial name Dengvaxia®) is a Sanofi Pasteur dengue tetravalent vaccine (live attenuated), that has been licensed for the prevention of dengue in more than 10 countries in Latin America and Asia Pacific.It is indicated for use in individuals aged 9-45 or 9-60 years (depending on country license) living in endemic areas, using a three-dose series on a 0/6/12-month schedule.CYD-TDV has been shown to protect against virologically confirmed dengue and severe dengue, and no significant safety signals have been observed in persons aged nine years and over. Its introduction should complement existing dengue surveillance, mosquito vector control, and dengue case management. Dengue risk is highly variable between and within countries, and thus priority for using the vaccine will vary accordingly.

Development of a Toolkit for Implementing the Dengue Vaccine

AMP Services has been developing a toolkit for dengue vaccination program, composed of a series of modules and interactive documents. The purpose is to summarize key accessible information to help decision makers and program planners (including Ministry of Health staff and NITAG members) make country decisions on dengue vaccine introduction.

Toolkit Composition

The dengue vaccination program toolkit includes:

The Dengue Vaccination Program Toolkit is available in English, Spanish, and Portuguese, to facilitate its use in Asia Pacific and Latin America regions.

Development Process

The development of the toolkit started in February 2016 and follows an incremental and interactive process, with the inclusion of feedback from country consultations, international meetings and experts, World Health Organization (WHO) recommendations, international organizations’ reports, and scientific literature. The material will be regularly updated. 

As of November 2016, a systematic collection of comments, suggestions, and experiences is being organized on this page. Please download the modules and send your comments and experiences to the following email address: denguetoolkit@aamp.org.
Your message will be acknowledged and will help to improve the dengue vaccination program toolkit.